Experimental Drugs for Neuropathic Pain

Author(s): Kinga Salat*, Beata Gryzlo, Katarzyna Kulig.

Journal Name: Current Neuropharmacology

Volume 16 , Issue 8 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Neuropathic pain (NP) is an important public health problem and despite recent progress in the understanding, diagnosis, pathophysiological mechanisms and the treatment of NP, many patients remain refractory to pharmacotherapy.

Objective: Currently used drugs have limited efficacy and dose-limiting adverse effects, and thus there is a substantial need for further development of novel medications for its treatment. Alternatively, drugs approved for use in diseases other than NP can be applied as experimental for NP conditions. This paper covers advances in the field of NP treatment.

Results: The prime focus of this paper is on drugs with well-established pharmacological activity whose current therapeutic applications are distinct from NP. These drugs could be a potential novel treatment of NP. Data from preclinical studies and clinical trials on these experimental drugs are presented. The development of advanced methods of genomics enabled to propose new targets for drugs which could be effective in the NP treatment.

Conclusion: Experimental drugs for NP can be a treatment option which should be tailor-made for each individual on the basis of pain features, previous therapies, associated clinical conditions, recurrence of pain, adverse effects, contraindications and patients’ preferences. At present, there are only some agents which may have potential as novel treatments. Increasing knowledge about mechanisms underlying NP, mechanisms of drug action, as well as available data from preclinical and clinical studies make botulinum toxin A, minocycline, ambroxol, statins and PPAR agonists (ATx086001) promising potential future treatment options.

Keywords: Neuropathic pain, adrenergic β2 receptors agonists, histamine H3 receptors, TRPA1 channels, T-type calcium channels, p38 mitogen-activated protein kinase, 3-hydroxy-3-methyl glutaryl coenzyme A reductase, reactive oxygen species.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 8
Year: 2018
Page: [1193 - 1209]
Pages: 17
DOI: 10.2174/1570159X16666180510151241
Price: $58

Article Metrics

PDF: 42
HTML: 3
PRC: 1